Comparative Pharmacology
Head-to-head clinical analysis: AMTURNIDE versus REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMTURNIDE versus REGROTON.
AMTURNIDE vs REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
10 mg to 20 mg orally once daily, with or without food.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination